Completing a process which began one year and one week earlier, the United States Patent and Trademark Office (USPTO) published a final rule in the Federal Register on October 21, 2016 which will change the fees for forty-two different trademark filings.
The USPTO Patent Trial and Appeals Board (PTAB) declined to institute Inter Partes Review (IPR) proceedings against three Biogen Idec TYSABRI patents.
To the extent you haven’t yet had a chance to fully digest the significant rule changes about to go into effect in all pending TTAB (Trademark Trial and Appeal Board) cases at the USPTO (United States Patent and Trademark Office) on January 14, 2017, now is your chance to hear how they will impact your cases and learn strategies for mastering them.
The USPTO has published a proposed fee schedule for patent fees likely to take effect October 1, 2017–the start of the USPTO’s next fiscal year.
On September 26, 2016, the U.S. Court of Appeals for the Federal Circuit declined to review in a unanimous en banc decision a panel Federal Circuit decision affirming that the Patent Trial and Appeal Board (the “Board”) at the Patent and Trademark Office (“USPTO”) could hear new evidence during a trial, evidence that was not cited by the Board in its decision to institute review under the America Invents Act (“AIA”).
Don’t Be Offended: Supreme Court Set to Decide Whether Offensive Trademark Ban Violates First Amendment
The United States Supreme Court, on September 29, 2016, granted certiorari in a case involving petitioner Simon Tam, his band, The Slants, and the band’s attempt to register their band name as a trademark.
On Thursday morning the Supreme Court’s new docket moved ever closer with the announcement of eight new cases they would be hearing. One of those cases has seemed like an inevitability for a long time, and it’s got a lot of cases riding on it.
In July 2016, the USPTO launched the Cancer Immunotherapy Pilot Program to provide a fast-track review for cancer immunotherapy-related patent applications without the need for applicants to pay a petition fee.
Recent Federal Circuit cases provide direction on how to satisfy the PTO or the federal courts that software is eligible for a patent.